{"title":"Improvement of Vestibular Neuritis in a Patient with Psoriatic Arthritis following Ixekizumab Administration","authors":"Sherry Ershadi, Shivkar Amara, M. Lebwohl","doi":"10.25251/skin.8.4.10","DOIUrl":null,"url":null,"abstract":"Psoriatic arthritis (PsA) is a chronic inflammatory condition commonly affecting peripheral joints and the skin. Recent studies have shown an association between PsA and vestibulocochlear dysfunction. Here, we present the case of a 43 year-old male with a history of controlled psoriasis (Pso) and PsA who presented with sudden-onset severe vertigo, nausea, and vomiting. Diagnostic evaluation ruled out a central etiology, leading to a diagnosis of vestibular neuritis of unknown origin. Despite minimal improvement with conventional medications, the patient experienced significant relief from vertigo symptoms following treatment with ixekizumab, an IL-17 inhibitor used to manage his PsA and Pso. This case highlights a potential therapeutic effect of biological agents on vestibular dysfunction associated with PsA. Future research in this area may provide insights into novel treatment strategies for vestibular symptoms in patients with PsA. ","PeriodicalId":22013,"journal":{"name":"SKIN The Journal of Cutaneous Medicine","volume":"126 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SKIN The Journal of Cutaneous Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25251/skin.8.4.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory condition commonly affecting peripheral joints and the skin. Recent studies have shown an association between PsA and vestibulocochlear dysfunction. Here, we present the case of a 43 year-old male with a history of controlled psoriasis (Pso) and PsA who presented with sudden-onset severe vertigo, nausea, and vomiting. Diagnostic evaluation ruled out a central etiology, leading to a diagnosis of vestibular neuritis of unknown origin. Despite minimal improvement with conventional medications, the patient experienced significant relief from vertigo symptoms following treatment with ixekizumab, an IL-17 inhibitor used to manage his PsA and Pso. This case highlights a potential therapeutic effect of biological agents on vestibular dysfunction associated with PsA. Future research in this area may provide insights into novel treatment strategies for vestibular symptoms in patients with PsA.